CAPR capricor.com Net earnings per share for the last 12 months

Chart volatility is driven by fierce competition in the cell therapy sector and the risks associated with genetic innovations. The financial foundation relies on the closed-loop cycle of the Capricor Therapeutics (CAPR) CAP-1002 platform and the modernization of plants to increase drug synthesis. The annual net income per share trend demonstrates current dynamics, where the value of -2.63 reflects the balance of the asset yield metric.

CAPR Capricor Therapeutics Earnings per share for the trailing year (07/04/2022 - 11/14/2026)

Capricor Therapeutics Inc. - analytical breakdowns and key metrics (CAPR)

- stock price and consensus target price:

Stock Price Capricor|CAPR - Average Forecast Price

- market capitalization data:

Market Valuation Capricor Therapeutics, Inc.|CAPR - Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Capricor Therapeutics|CAPR - Accounting Value of Company|Market Value to Book Value Ratio capricor.com|CAPR - Company Assets

- debt level and financial liquidity data:

- earnings and multiples data:

CAPR - Net Income|Projected Future Earnings Capricor Therapeutics|CAPR - P/E Multiple|Future Price to Earnings Capricor|CAPR - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Capricor Therapeutics, Inc.|CAPR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Capricor Therapeutics|CAPR - Net earnings per share for the last four quarters|Quarterly EPS earnings growth capricor.com|CAPR - Net earnings per share growth this year|Net earnings per share growth forecast for next year Capricor Therapeutics

- issuer revenue and sales details:

CAPR - Company Total Revenue|Company Projected Revenue Capricor|CAPR - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Capricor Therapeutics, Inc.

Basic company analysis:capricor.com (CAPR)

Capricor Therapeutics (CAPR) investments in the development of cell technologies to combat Duchenne muscular dystrophy define its profit profile, where R&D expenses directly impact the bottom line. Analyzing annual net income per share allows for an assessment of the business's real equity yield, adjusted for issuance volume, which helps investors identify the company's fundamental stability through the price action on this chart.

Analysis of competing companies